Viral Bad News Sent by EVAIL
Open Access
- 18 June 2021
- Vol. 13 (6), 1168
- https://doi.org/10.3390/v13061168
Abstract
This article reviews the current knowledge on how viruses may utilize Extracellular Vesicle Assisted Inflammatory Load (EVAIL) to exert pathologic activities. Viruses are classically considered to exert their pathologic actions through acute or chronic infection followed by the host response. This host response causes the release of cytokines leading to vascular endothelial cell dysfunction and cardiovascular complications. However, viruses may employ an alternative pathway to soluble cytokine-induced pathologies—by initiating the release of extracellular vesicles (EVs), including exosomes. The best-understood example of this alternative pathway is human immunodeficiency virus (HIV)-elicited EVs and their propensity to harm vascular endothelial cells. Specifically, an HIV-encoded accessory protein called the “negative factor” (Nef) was demonstrated in EVs from the body fluids of HIV patients on successful combined antiretroviral therapy (ART); it was also demonstrated to be sufficient in inducing endothelial and cardiovascular dysfunction. This review will highlight HIV-Nef as an example of how HIV can produce EVs loaded with proinflammatory cargo to disseminate cardiovascular pathologies. It will further discuss whether EV production can explain SARS-CoV-2-mediated pulmonary and cardiovascular pathologies.Keywords
Funding Information
- National Institutes of Health (NIHBLI: 1R01HL154859-01)
This publication has 108 references indexed in Scilit:
- Persistent Inflammation and Endothelial Activation in HIV-1 Infected Patients after 12 Years of Antiretroviral TherapyPLOS ONE, 2013
- Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohortEuropean Heart Journal, 2011
- Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart DiseaseArchives of Internal Medicine, 2011
- Dyslipidemia and lipid management in HIV-infected patientsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- HIV Type 1 Nef Is Released from Infected Cells in CD45+Microvesicles and Is Present in the Plasma of HIV-Infected IndividualsAIDS Research and Human Retroviruses, 2011
- Mutation of the ATP Cassette Binding Transporter A1 (ABCA1) C-Terminus Disrupts HIV-1 Nef Binding but Does Not Block the Nef Enhancement of ABCA1 Protein DegradationBiochemistry, 2010
- Circulating Nef Induces Dyslipidemia in Simian Immunodeficiency Virus–Infected Macaques by Suppressing Cholesterol EffluxThe Journal of Infectious Diseases, 2010
- Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapyAIDS, 2010
- Genetic Characterization of HIV Type 1 Nef-Induced Vesicle SecretionAIDS Research and Human Retroviruses, 2010
- Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM studyAIDS, 2009